Endocrine Abstracts

Experimental, clinical and/or epidemiological evidence points to a role for prolactin (PRL) in the promotion of benign and malignant tumors of the breast and the prostate. However, therapies reducing PRL levels (dopamine agonists) are currently not considered for the treatment of these pathologies. Dopamine agonists only target PRL secretion from the pituitary, while recent observations suggest that the involvement of autocrine PRL is perhaps even more relevant than circulatin...